BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field

Boehringer Ingelheim (BI) Japan announced that it will discontinue the development of its chronic hepatitis C treatment faldaprevir for use in combination with an interferon (IFN), and will call off its entry into the field of hepatitis C. BI Japan...read more